Preclinical anti-tumour activity of various intraperitoneal cytostatics in vivo (mouse model) for the treatment of ovarian cancer

被引：0
|
作者：
Dowaji, J.
Donner, A.
Breidenbach, M.
Rath, W.
机构：
[1] Univ Klinikum Aachen, Gynakol & Geburtshilfe, Aachen, Germany
[2] Univ Klinikum Aachen, Inst Pathol, Aachen, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2007年 / 67卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：396 / 396
页数：1
相关论文
共 50 条
  • [41] Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system
    Kishima, H
    Shimizu, K
    Miyao, Y
    Mabuchi, E
    Tamura, K
    Tamura, M
    Sasaki, M
    Hayakawa, T
    BRITISH JOURNAL OF CANCER, 1998, 78 (04) : 446 - 453
  • [42] Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model
    Geller, Melissa A.
    Knorr, David A.
    Hermanson, David A.
    Pribyl, Lee
    Bendzick, Laura
    McCullar, Valarie
    Miller, Jeffrey S.
    Kaufman, Dan S.
    CYTOTHERAPY, 2013, 15 (10) : 1297 - 1306
  • [43] Tumor growth Inhibition via intraperitoneal application of Carboplatin in (mouse model) treatment for ovarian cancer
    Dowaji, J.
    Rath, W.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S70 - S71
  • [44] Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer
    Huixin Yu
    Jeroen J. M. A. Hendrikx
    Sven Rottenberg
    Jan H. M. Schellens
    Jos H. Beijnen
    Alwin D. R. Huitema
    The AAPS Journal, 2016, 18 : 362 - 371
  • [45] Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer
    Yu, Huixin
    Hendrikx, Jeroen J. M. A.
    Rottenberg, Sven
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    AAPS JOURNAL, 2016, 18 (02): : 362 - 371
  • [46] The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models
    Uchegbu, IF
    Double, JA
    Kelland, LR
    Turton, JA
    Florence, AT
    JOURNAL OF DRUG TARGETING, 1996, 3 (05) : 399 - 409
  • [47] Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model
    Heinemann, L.
    Simpson, G.
    Harrington, K.
    Melcher, A.
    Coffey, M. C.
    Pandha, H. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 99 - 99
  • [48] Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
    Samson, Adel
    Bentham, Matthew J.
    Scott, Karen
    Nuovo, Gerard
    Bloy, Abigail
    Appleton, Elizabeth
    Adair, Robert A.
    Dave, Rajiv
    Peckham-Cooper, Adam
    Toogood, Giles
    Nagamori, Seishi
    Coffey, Matthew
    Vile, Richard
    Harrington, Kevin
    Selby, Peter
    Errington-Mais, Fiona
    Melcher, Alan
    Griffin, Stephen
    GUT, 2018, 67 (03) : 562 - 573
  • [49] Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response
    Gill, Kheshwant S.
    Fernandes, Philana
    O'Donovan, Tracey R.
    McKenna, Sharon L.
    Doddakula, Kishore K.
    Power, Derek G.
    Soden, Declan M.
    Forde, Patrick F.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2016, 1866 (01): : 87 - 105
  • [50] α-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability
    Neuzil, J
    Zhao, M
    Ostermann, G
    Sticha, M
    Gellert, N
    Weber, C
    Eaton, JW
    Brunk, UT
    BIOCHEMICAL JOURNAL, 2002, 362 (03) : 709 - 715
12345